[go: up one dir, main page]

ZA200806094B - Methods for obtaining immortalized antibody secreting cells - Google Patents

Methods for obtaining immortalized antibody secreting cells

Info

Publication number
ZA200806094B
ZA200806094B ZA200806094A ZA200806094A ZA200806094B ZA 200806094 B ZA200806094 B ZA 200806094B ZA 200806094 A ZA200806094 A ZA 200806094A ZA 200806094 A ZA200806094 A ZA 200806094A ZA 200806094 B ZA200806094 B ZA 200806094B
Authority
ZA
South Africa
Prior art keywords
methods
cells
human
secrete
secreting cells
Prior art date
Application number
ZA200806094A
Other languages
English (en)
Inventor
Garotta Gianni
Funaro Ada
Murphy Marianne
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of ZA200806094B publication Critical patent/ZA200806094B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200806094A 2005-12-16 2008-07-14 Methods for obtaining immortalized antibody secreting cells ZA200806094B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2005056871 2005-12-16

Publications (1)

Publication Number Publication Date
ZA200806094B true ZA200806094B (en) 2009-06-24

Family

ID=36685876

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200806094A ZA200806094B (en) 2005-12-16 2008-07-14 Methods for obtaining immortalized antibody secreting cells
ZA200904907A ZA200904907B (en) 2005-12-16 2009-07-14 Antibodies against human cytomegalovirus (hCMV)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200904907A ZA200904907B (en) 2005-12-16 2009-07-14 Antibodies against human cytomegalovirus (hCMV)

Country Status (19)

Country Link
US (1) US8338172B2 (xx)
EP (1) EP1974020B1 (xx)
JP (2) JP5431730B2 (xx)
KR (1) KR101508945B1 (xx)
CN (1) CN101374944B (xx)
AT (1) ATE513034T1 (xx)
AU (1) AU2006325236B2 (xx)
BR (1) BRPI0619908A2 (xx)
CA (1) CA2633601C (xx)
DK (1) DK1974020T3 (xx)
EA (1) EA019505B1 (xx)
ES (1) ES2367322T3 (xx)
IL (1) IL192095A0 (xx)
NO (1) NO20083160L (xx)
NZ (1) NZ569816A (xx)
PL (1) PL1974020T3 (xx)
PT (1) PT1974020E (xx)
WO (1) WO2007068758A1 (xx)
ZA (2) ZA200806094B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
EP3293269A1 (en) * 2007-08-03 2018-03-14 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
US20110171233A1 (en) * 2007-08-22 2011-07-14 Ribovax Biotechnologies S.A. Antibodies Against Human Cytomegalovirus (HCMV)
EP2352759B1 (en) 2008-07-16 2017-11-01 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8703486B2 (en) 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
JP6174320B2 (ja) 2009-11-17 2017-08-02 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトヌクレオリンに対するヒトモノクローナル抗体
JP5833565B2 (ja) 2009-12-23 2015-12-16 ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ ヒトサイトメガロウイルスに対する結合メンバー
EP2400298B1 (en) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
CA3062786C (en) 2010-07-09 2022-04-19 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN102839152A (zh) * 2011-06-20 2012-12-26 中国科学院上海生命科学研究院 一种快速高效获得抗原特异性b细胞的方法
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
AU2013206788B2 (en) 2011-12-28 2017-11-30 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2014093786A1 (en) * 2012-12-14 2014-06-19 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
CA2896908A1 (en) * 2013-01-03 2014-07-10 Merck Patent Gmbh Method of producing secretable antibodies by expression in saccharomyces cerevisiae
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3562936B1 (en) * 2017-01-02 2024-05-22 F. Hoffmann-La Roche AG B-cell cultivation method
JP2020515522A (ja) * 2017-01-27 2020-05-28 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN120239745A (zh) * 2022-12-06 2025-07-01 北山拉贝斯株式会社 永生化细胞的制造方法
CN117230258B (zh) * 2023-11-10 2024-04-09 苏州驾玉生物医药有限公司 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法
CN119285758B (zh) * 2024-10-31 2025-07-01 上海百英生物科技股份有限公司 一种基于b细胞永生化的单个b细胞抗体开发方法及其应用
CN120272432A (zh) * 2025-03-25 2025-07-08 佛山市妇幼保健院 一种脊髓性肌萎缩症质控品及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
WO1991004336A1 (en) * 1989-09-19 1991-04-04 Centocor, Inc. Method for improving human monoclonal antibody production
EP0440147B2 (de) 1990-02-01 2014-05-14 Siemens Healthcare Diagnostics Products GmbH Herstellung und Verwendung von Genbanken menschlicher Antikörper ("Human-Antikörper-Bibliotheken")
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
FR2817875B1 (fr) * 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2007063415A2 (en) * 2005-08-23 2007-06-07 Iq Corporation Methods of producing stable b-lymphocytes

Also Published As

Publication number Publication date
CN101374944B (zh) 2012-02-08
AU2006325236A1 (en) 2007-06-21
KR20080097181A (ko) 2008-11-04
EP1974020B1 (en) 2011-06-15
CN101374944A (zh) 2009-02-25
WO2007068758A1 (en) 2007-06-21
AU2006325236B2 (en) 2011-11-10
EP1974020A1 (en) 2008-10-01
HK1127783A1 (en) 2009-10-09
ZA200904907B (en) 2010-04-28
US8338172B2 (en) 2012-12-25
EA019505B1 (ru) 2014-04-30
IL192095A0 (en) 2008-12-29
NO20083160L (no) 2008-09-10
ATE513034T1 (de) 2011-07-15
JP5431730B2 (ja) 2014-03-05
PT1974020E (pt) 2011-08-26
BRPI0619908A2 (pt) 2011-10-25
NZ569816A (en) 2011-10-28
DK1974020T3 (da) 2011-10-03
PL1974020T3 (pl) 2011-11-30
KR101508945B1 (ko) 2015-04-08
JP2009519026A (ja) 2009-05-14
CA2633601A1 (en) 2007-06-21
EA200870062A1 (ru) 2009-04-28
JP2013255515A (ja) 2013-12-26
US20090270268A1 (en) 2009-10-29
ES2367322T3 (es) 2011-11-02
CA2633601C (en) 2015-06-30

Similar Documents

Publication Publication Date Title
ZA200806094B (en) Methods for obtaining immortalized antibody secreting cells
US12351825B2 (en) Soluble antibody complexes for T cell or NK cell activation and expansion
Izawa et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70–CD27 pathway in immunity to Epstein-Barr virus infection
Stemberger et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting
PH12020500160A1 (en) Reagents for expanding cells expressing recombinant receptors
MY150553A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
Dang et al. Soluble CD27 induces IgG production through activation of antigen‐primed B cells
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
WO2009035738A3 (en) Use of antibody secreting cell elispot to assess antibody responses following antigen exposure
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
WO2011050985A8 (en) Clonal expansion of b cells
Mangare et al. Robust identification of suitable T-cell subsets for personalized CMV-specific T-cell immunotherapy using CD45RA and CD62L microbeads
Correa et al. Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells
Vasquez et al. Rapid proliferation and differentiation of a subset of circulating IgM memory B cells to a CpG/cytokine stimulus in vitro
Scholzen et al. Expansion of IgG+ B-cells during mitogen stimulation for memory B-cell ELISpot analysis is influenced by size and composition of the B-cell pool
WO2009045075A3 (en) A monoclonal antibody specific to human embryonic stem cell, a hybridoma secreting the same and a method for detecting or isolating non-differenced embryonic stem cell
Hayashi et al. Generation of anti‐porcine CD 69 monoclonal antibodies and their usefulness to evaluate early activation of cellular immunity by flow cytometric analysis
Zhang et al. Analysis of the Heterogeneity of CD4+ CD25+ T Cell TCR β CDR3 Repertoires in Breast Tumor Tissues, Lung Metastatic Tissues, and Spleens from 4T1 Tumor‐Bearing BALB/c Mice
Gao et al. P032 Compound HLA/KIR genotypes influence risk of nasopharyngeal carcinoma in a Southern Chinese cohort
WO2006089002A3 (en) Method for high throughput screening for antibodies and proteins inducing apoptosis
UA72439U (ru) Тест-система иммуноферментная для качественного и полуколичественного определения антител класса igg к вирусам простого герпеса 2 типа, унифицированная "dia-hsv 2-igg-u"
Manna et al. Autologous crossmatches: How useful are they in the evaluation of positive donor flow cytometric crossmatches?